Myriad Genetics: John Henderson, Daniel Spiegelman
Myriad Genetics said that John Henderson will retire from its board of directors at its annual meeting in December. Henderson chaired the board from April 2005 through March 2020, at which point Louise Phanstiel was elected to serve as chair.
The company has also elected to its board of directors Daniel Spiegelman, who most recently served as executive VP and CFO of BioMarin Pharmaceuticals. After retiring from that role, Spiegelman has been serving on the board of Tizona Therapeutics, as well on the boards of several biotech firms.
Pacific Biosciences: Eric Schaefer
On May 26, Pacific Biosciences appointed Eric Schaefer to the role of vice president and chief accounting officer, effective immediately. He succeeds Susan Barnes as the principal accounting officer.
Schaefer previously served as PacBio's senior director, corporate controller. He joined the firm in 2012 from PricewaterhouseCoopers and is a certified public accountant.
Freenome: Bill Quirk, Gary Reedy
Freenome has hired Bill Quirk as its CFO. Prior to joining Freenome, Quirk served as a managing director in the equity research division of investment bank Piper Sandler.
The company also announced that Gary Reedy has joined its board of directors as an observer. Reedy became CEO of the American Cancer Society in April 2015, having worked with the organization for more than 20 years. He has had a 37-year career as a healthcare business and advocacy leader, most recently as worldwide VP of government affairs and policy at Johnson & Johnson. He also held senior leadership positions with SmithKline Beecham, Centocor, and Johnson & Johnson.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.